S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.60%)
CGC   17.64 (+15.14%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
T   37.18 (-2.16%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
BAC   32.69 (-0.76%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.60%)
CGC   17.64 (+15.14%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
T   37.18 (-2.16%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
BAC   32.69 (-0.76%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.60%)
CGC   17.64 (+15.14%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
T   37.18 (-2.16%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
BAC   32.69 (-0.76%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.60%)
CGC   17.64 (+15.14%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
T   37.18 (-2.16%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
BAC   32.69 (-0.76%)
DIS   146.93 (-0.98%)
Log in

Daxor Stock Price, Forecast & Analysis (NYSEAMERICAN:DXR)

$9.46
-0.14 (-1.46 %)
(As of 11/20/2019 04:00 PM ET)
Today's Range
$9.45
Now: $9.46
$9.50
50-Day Range N/A
52-Week Range
$5.75
Now: $9.46
$19.95
Volume1,346 shs
Average Volume22,491 shs
Market Capitalization$35.45 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:DXR
CUSIPN/A
Phone+1-212-3308500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$35.45 million
Next Earnings DateN/A
OptionableNot Optionable

Receive DXR News and Ratings via Email

Sign-up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter.


Daxor (NYSEAMERICAN:DXR) Frequently Asked Questions

What is Daxor's stock symbol?

Daxor trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "DXR."

What price target have analysts set for DXR?

3 equities research analysts have issued 12 month price targets for Daxor's shares. Their forecasts range from $18.00 to $22.00. On average, they expect Daxor's stock price to reach $20.00 in the next year. This suggests a possible upside of 111.4% from the stock's current price. View Analyst Price Targets for Daxor.

What is the consensus analysts' recommendation for Daxor?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Daxor in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Daxor.

Has Daxor been receiving favorable news coverage?

News stories about DXR stock have been trending somewhat negative on Wednesday, according to InfoTrie. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Daxor earned a news sentiment score of -1.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Daxor.

Are investors shorting Daxor?

Daxor saw a drop in short interest in October. As of October 15th, there was short interest totalling 73,800 shares, a drop of 9.7% from the September 15th total of 81,700 shares. Based on an average trading volume of 4,100 shares, the short-interest ratio is presently 18.0 days. Approximately 9.2% of the company's shares are short sold. View Daxor's Current Options Chain.

Who are some of Daxor's key competitors?

What other stocks do shareholders of Daxor own?

Who are Daxor's key executives?

Daxor's management team includes the folowing people:
  • Mr. Michael Richard Feldschuh, Chairman, Pres & CEO (Age 50)
  • Mr. Jonathan Adam Feldschuh, Chief Scientific Officer & Director (Age 54)
  • Mr. Robert J. Michel CPA, Chief Financial Officer (Age 62)
  • Ms. Kathryn A. Kornafel, VP of Marketing & Commercial Devel.
  • Mr. Guido Manzo, VP of Sales

How do I buy shares of Daxor?

Shares of DXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Daxor's stock price today?

One share of DXR stock can currently be purchased for approximately $9.46.

How big of a company is Daxor?

Daxor has a market capitalization of $35.45 million. View Additional Information About Daxor.

What is Daxor's official website?

The official website for Daxor is http://www.daxor.com/.

How can I contact Daxor?

Daxor's mailing address is 350 5th Ave Ste 4740, NEW YORK, NY 10118-0002, United States. The company can be reached via phone at +1-212-3308500.


MarketBeat Community Rating for Daxor (NYSEAMERICAN DXR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  244
MarketBeat's community ratings are surveys of what our community members think about Daxor and other stocks. Vote "Outperform" if you believe DXR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DXR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel